BRIEF-Onco Therapy Science to start Phase I clinical study for breast cancer patients in U.S.

* Says the co will conduct Phase I clinical study of OTS167,

a MELK specific inhibitor, for breast cancer patients following

the acceptance of the protocol by the U.S. Food and Drug

Administration

Read more